{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "VATC|ANTIHEMORRHAGICS|ANTIFIBRINOLYTICS|Proteinase inhibitors" in comments (approximate match)
Showing 1 - 2 of 2 results
Status:
Possibly Marketed Outside US
Source:
NCT04338906: Phase 4 Interventional Withdrawn COVID
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Camostat mesilate (FOY-305) is a synthetic f low-molecular weight protease inhibitor. It is able to inhibit trypsin, prostasin, matriptase and plasma kallikrein. In addition camostat attenuates airway epithelial sodium channel function and enhances mucociliary clearance. Camostat mesilate tablets (FOIPAN®) are approved in Japan and used for the treatment of remission of acute symptoms of chronic pancreatitis and postoperative reflux esophagitis.
Status:
US Previously Marketed
Source:
TRASYLOL by BAYER HLTHCARE
(1993)
Source URL:
First approved in 1993
Source:
TRASYLOL by BAYER HLTHCARE
Source URL:
Class:
PROTEIN
